chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I got diagnosed with Covid 19 on June 26,2021. My parents were diagnosed with Covid 19 on the same day.; I got diagnosed with Covid 19 on June 26,2021. My parents were diagnosed with Covid 19 on the same day.; This is a spontaneous report from a Pfizer sponsored program Pfizer. This consumer reported for a male patient (reporter's father) that, A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on as a DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. Reporter said that, my whole family is vaccinated with the Covid 19 vaccine by Pfizer since Feb2021 and I got diagnosed with Covid 19 on 26Jun2021. My parents were diagnosed with Covid 19 on the same day. MD said we had the virus breakthrough. It seems to be happening to many people. Outcome of unknown The patient underwent lab tests and procedures which included sars-cov-2 test which was, positive on 26Jun2021 (got diagnosed with Covid 19 on 26Jun2021).  Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021884456 Same reporter/drug/AE, different patient.
I received the vaccine at 0930 am 1/6, about 6 hours later I started feeling extreme fatigue and a slight sore throat. I left work early at that time. When I got home I couldn't stay awake and fell asleep around 6pm. Then starting having GI distress cramping, pain and diarrhea around 9pm-11pm. At 2 am I woke up with chills and fever, I took a Tylenol around 3-4 m and then broke out if huge sweat, then finally fell asleep. 1/7/21 I mostly have soreness, headache and fatigue now.
Initial report received from a nurse via company representative on 29 June 2011. An unknown patient (date of birth, age, and gender not reported) had received a dose of ADACEL and MENACTRA (lot numbers not reported) on an unspecified date. At an unspecified amount of time following the vaccinations, the patient experienced an extreme headache and fatigue persisting for more than 2 days, which was concerning to both the parent and nursing staff. It was not reported whether the patient required medical evaluation or treatment. No other information, nor the recovery status were provided. Documents held by sender: None.
First outbreak of shingles both sides of face. 2nd outbreak of shingles; both sides of face. Never any shingles rash prior to vaccine 2/08.
I am on day 11 since vaccination and site of injected has remained ?swollen? and today has a 2-3 inch red mark that is warm to the touch.
This spontaneous report has been received from a nurse referring to a patient of unknown age and gender. The patient's medical history, drug reactions, allergies and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with VAQTA, (strength, route of administration, frequency, and dose were not provided),  lot # M017982 and expiration date 13-SEP-2017 for prophylaxis. The nurse stated that the vaccine was stored in a syringe for 26 hours in the refrigerator between 36F to 46F, she also reported that the vaccine did not have any previous temperature excursions. No adverse symptoms were reported nor product quality complaint was not involved. Additional information has been requested.
Patient called 6/23/15 1015am reporting after she received her PREVNAR 13 she experienced moderate itching of her chest that night.
Left arm, chest, and leg pain approximately 7-10 days after first Pfizer shot. My hematologist sent me into radiology to get imaging done and a new DVT was found in my left arm and also near my left clavicle. I was hospitalized for 3 days and was switched from Eliquis to Warfarin.
On Friday night at about 6 PM, I developed a funny postnasal discharge I had never had before. I took a home COVID-19 test and immediately got a positive result. I called a doctor friend of mine and got a Paxlovid prescription, which I began on Saturday morning. The symptoms progressed rapidly and significantly. My oxygen saturation level dropped to the 70s at rest, and my heartrate was 100-110 at rest. I began producing copious amounts of sputum; I had to use a bath towel instead of a handkerchief to capture it. This copious sputum lasted all five days that I took Paxlovid. On the fifth day, I added a Z-Pak to my regimen, and my sputum production decreased within 24 hours. I think I had had a super infection, because the sputum quality went from green to clear. I lost 12 lbs. during my 10-day period with COVID-19. The Paxlovid left a terrible taste in my mouth; it was so bad that I almost stopped taking it. On the fifth day of Paxlovid therapy, I tested negative. After I started the Z-Pak, my oxygenation level returned to the 90s within three days. I had profound fatigue, and oxygenation levels would dip into the 80s for several weeks after any activity for about six weeks afterwards. I am now back to normal, but I still haven't regained the weight I lost during my bout with COVID-19. However, my oxygenation now stays at its baseline, and I am able to do 18 holes of golf and swim laps with no problem.
Woke up 7-16-11 with redness and warmth at site of injection with parameters approx 120 mm x 130 mm. No rash. Sunday (7-17-11) noted itching on both lower legs. Used hydrocortisone with relief. No breathing problems. No itching at site of inject. 7-18-11 area still red, slightly warm approx size 120 x 130 mm but not as painful. Pt use emu oil for relief topically.
Felt flush and throat started to get scratchy and  started to get tighter and was having difficulty swallowing about 4 minutes after vaccination.  Continued to get more flush and laid down.  Rapid response was called and taken to the emergency room.
Hives; Nausea; A spontaneous report was received from a non HCP concerning a 45-Year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced hives and nausea.   The patient was reported with an history of Anaphylaxis in the past.   No relevant concomitant medications were reported.     On 11 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: unknown) intramuscularly for prophylaxis of COVID-19 infection.   On 11 Jan 2021, The patient experienced Urticaria (Hives) and Nausea with seriousness criteria of Hospitalization.   Laboratory details are not  provided.   No treatment information was provided.    Action taken with mRNA-1273 in response to the events was not reported.    The outcome of the event is unknown.; Reporter's Comments: This case concerns a 45-year-old female, with medical history of anaphylaxis, was hospitalized with serious unexpected events of urticaria and nausea.  The events occurred the same day as the first dose of mRNA-1273. Treated with Benadryl. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
PATIENT WAS EXTREMELY NERVOUS, STATED DOES NOT LIKE NEEDLES.  WITHIN 2 MINUTES FELT CHEST TIGHTNESS, LIGHTHEADEDNESS, STARTED SHAKING AND EYES ROLLED UP BEFORE PASSING OUT.  COME TO WITHIN A FEW SECONDS BUT WAS NOT  COHERENT.  COULDN'T ANSWER BASIC QUESTIONS AND LOOKED AS IF WAS GOINT TO PASS OUT AGAIN.  COULD NOT STAND, TALK ETC.  HE WAS LIKE THIS FOR 10 MINUTES OR SO.  CALLED 911 THEY STATED TO  LAY PATEINT CAREFULLY ON THE FLOOR TO RECOVER BLOOD FLOW UNTIL THEY COULD GET THERE.  PATEINT STARTED COMING BACK AROUND WITHIN THE NEXT 5 MINUTES.  MOTHER REFUSED LEAVING IN AMBULANCE BELIEVED SON WOULD BE FINE.
The patient was administered 2nd dose of Pfizer vaccine in right arm. Within seconds, the patient complained of itching to his neck, head, arms, and shoulders.  He denied difficulty breathing; VS were nromal. Affected areas appeared red due to scratching, but no other visible lesions noted. Pt denies history of reactions to medications and past immunizations.
He is a 81 y.o. male patient of a MD with history of anxiety, DM2, A. fib, CAD, HTN, HLD, prior MI, arthritis, presented to Hospital with generalized weakness, fatigue.       Covid-19 Virus Infection Date of onset of symptoms: 1/1 Symptoms present on admission: cough, congestion, generalized weakness, fatigue Date of covid positive test: 1/1 Vaccination status: vaccinated Imaging: CXR nonacute  Oxygen requirements on admission: RA Current oxygen requirements: RA Medical therapy: not indicated Anticipated special isolation end date: 1/7 if improving symptoms and afebrile off of antipyretics    AKI on CKD, improved  Etiology likely from  Baseline creatinine runs 1.5-1.8 Creatinine of 2.15 on admission peaked at 2.4 and 2 at discharge UA with protein otherwise not terribly remarkable Renal and bladder ultrasound with multiple simple appearing cyst in bilateral kidneys but no acute issues. S/p  IV fluids Hold home losartan until he has outpatient labs Resume home Lasix at discharge  To follow up with his Nephrologist for repeat labs in 1-2 weeks   BPH Continue home Flomax   DM2 Resume home Alogliptin at discharge    Elevated troponin Unclear why this was checked Troponin flat at 43 and 41 EKG reported as no acute changes No further inpatient work-up   CAD Hypertension Resume home statin, Plavix, Imdur, metoprolol, Ranexa Lasix and ARB as above
Fell numerous times during day.  While PT has gait and balance issues and walks with a walker, her condition markedly increased the day after the injection when she fell 4-5 times.  She returned to her normal the following day.  NOTE: 2-3 years ago when she didn't have the aforementioned issues, he received the first Shingrix injection, and experienced identical symptoms, falling numerous times.  She returned to normal by the following day.  Because of this, she was advised not to and did not receive the second Shingrix injection.  This was reported to you at that time
Pt recv vax on 11/5/98; on same day pt exp swelling & bruising of Rt arm, hot to touch, fever (100.6); tx=Tylenol #3 & Keflex
Positive COVID test/hospitalization after COVID vaccine Narrative: Patient received 1st dose of Moderna COVID-19 vaccine on 2/11/2021. Patient then presented to the ED on 2/20/21 where he tested COVID positive and reported that his onset of symptoms was around 2/17/2021. Patient had increasing oxygen requirements and was transferred to the MICU. Patient then had to be intubated on 2/28/21. On that day, he was started on dexamethasone 6mg x10days. He was not given remdesivir due to his late presentation following symptom onset. His hospital course was further complicated by AKI which resolved and superimposed MSSA pneumonia as well as MSSA bacteremia. He was extubated on 3/7 and was discharged on 3/12 to the COVID rehab unit. He received his 2nd Moderna COVID-19 vaccine 3/12/21 without issue.
Delayed fever and febrile seizure 9 days post MMR vaccination.  Pt had also received Dtap and Hep A vaccinations day of fever and febrile seizure.
pt recvd vax; redness at site, ha p/ dose 1; redness, itching, swelling at site, ha, shortness of breath, d after dose 2;
Mild ache and chills the night of the second dosage, which then subsided. Two days later, my wrists and ankles and ESPECIALLY my left TMJ became inflamed. The ankles ache went away after a couple of weeks. The wrists mostly subsided over a month or so. The left TMJ was very inflamed feeling for several months, although it seems to slowly be fading. For a long while it hurt to open my mouth. Daily aching in the side of my head is now infrequent, but the joint is still sensitive when I eat. There were no other proximate events (tick bite?) that would explain the left TMJ. It took me a couple of weeks to associate it with the Moderna vaccine. At first I just thought it was an initial Rheumatoid arthritis "attack." I have subsequently seen a rheumatologist who suggested blood tests for RA markets, which came back negative.
Information has been received from a consumer concerning her 16 month old nephew with no pertinent medical history and no allergies, who "about two weeks ago" on approximately 03 Apr 2006 was vaccinated with a dose of Varivax. There was no concomitant medication. Since he was administered the vaccine, also reported as "25 Apr 2006", the patient developed a rash below both knees. No medical attention was sought. The outcome was not recovered. No product quality complaint was involved. Additional information is not expected.
Dose administered >12 hours post puncture; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Dose administered >12 hours post puncture) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A22B) for COVID-19 vaccination.     Concurrent medical conditions included Obesity since 2018, Diabetes since 2018, Hypertension since 2019 and High cholesterol since 2018. Concomitant products included INSULIN GLARGINE (LANTUS), METFORMIN HYDROCHLORIDE, SITAGLIPTIN PHOSPHATE MONOHYDRATE (JANUMET) and ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.   On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-May-2022 at 10:40 AM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-May-2022 at 10:40 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Dose administered >12 hours post puncture). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Dose administered >12 hours post puncture) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No allergies were reported The vial was first punctured on 24-May-2022 at 8:30 am and administered on 25-May-2022 at 10.40am. Reporter was not aware of any adverse events after any of the vaccines and it is unknown if any treatment was given after any AE.
This spontaneous case was reported by a consumer and describes the occurrence of SKIN DISCOLORATION (SKIN DISCOLORATION TO UPPER BODY WITH SMALL DARKENED SKIN SPLOTCHES THAT COME AND GO), CONSTIPATION (Constipation), SINUS CONGESTION (Sinus congestion) and JOINT STIFFNESS (EPISODE OF INCREASED JOINT STIFFNESS) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Subcutaneous) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, the patient experienced SKIN DISCOLORATION (SKIN DISCOLORATION TO UPPER BODY WITH SMALL DARKENED SKIN SPLOTCHES THAT COME AND GO), CONSTIPATION (Constipation), SINUS CONGESTION (Sinus congestion) and JOINT STIFFNESS (EPISODE OF INCREASED JOINT STIFFNESS). At the time of the report, SKIN DISCOLORATION (SKIN DISCOLORATION TO UPPER BODY WITH SMALL DARKENED SKIN SPLOTCHES THAT COME AND GO) outcome was unknown and CONSTIPATION (Constipation), SINUS CONGESTION (Sinus congestion) and JOINT STIFFNESS (EPISODE OF INCREASED JOINT STIFFNESS) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Subcutaneous) was unknown. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Concomitant Drugs not reported. Co-suspect HUMIRA formulation was Solution for injection in pre-filled pen. The reporter's causality for the event of constipation, sinus congestion and skin discoloration to upper body with small, darkened skin splotches that come and go was not provided. The reporter causality for the event of episode of increased joint stiffness with Humira (Adalimumab) was no reasonable possibility. No treatment medication was provided by reporter.
vaccinia contamination on eczema; Secondary transmission from husband; This case was obtained from a scientific literature titled "Contact transmission of vaccinia to an infant diagnosed by viral culture and metagenomic sequencing", on date 11MAR2021.  Literature citation: Contact transmission of vaccinia to an infant diagnosed by viral culture and metagenomic sequencing. Open Forum Infect Dis. 2020.  This case refers to a female patient (infant's mother) whose "rash may have been a mild form of eczema vaccinatum" (PT: Eczema vaccinatum). It was reported that "an occult transmission from a recent vaccinee was considered" (PT: Secondary transmission). ACAM2000 (smallpox vaccine, live) was suspected of the infection.  The female had a history of moderate to severe atopic dermatitis and reported a recent illness and flare of her skin disease. On exam, she had numerous circular collarettes of scale over her forearms and arms from a vesicular eruption that began the week prior. Her rashes might be a mild form of eczema vaccinatum that were resolving without any intervention. She had not received any recent live-virus vaccinations and the possible transmission occurred  from her husband. As many military members in the father's workplace receive ACAM2000 vaccine, it was theoretically possible that contact transmission resulted in unrecognized secondary vaccinia infection.  Based on the available information in the article, 3 individual case safety reports 21000032LT (infant), 21000033LT (mother) and 21000034LT (father) were created and cross linked in the database.  Company Comment: The company agrees with the author that there was a secondary transmission from the father to the mother. A secondary transmission from other military personnel recently vaccinated, contamination is possible and cannot be ruled out; then tertiary contamination to a patient's history of eczema, the development of eczema vaccinatum is also possible. ACAM2000 is a live virus vaccine and has a potential to cause secondary transmission to household members and close contacts by accidental (contact) inoculation. The causality of eczema vaccinatum and secondary transmission is assessed as possible. The case does not meet the seriousness criteria but it will be submitted to the FDA as required.; Sender's Comments: The company agrees with the author that there was a secondary transmission from the father to the mother. A secondary transmission from other military personnel recently vaccinated, contamination is possible and cannot be ruled out; then tertiary contamination to a patient's history of eczema, the development of eczema vaccinatum is also possible. ACAM2000 is a live virus vaccine and has a potential to cause secondary transmission to household members and close contacts by accidental (contact) inoculation. The causality of eczema vaccinatum and secondary transmission is assessed as possible. The case does not meet the seriousness criteria but it will be submitted to the FDA as required.
March 5th: A.M. Left arm at injection site is swollen and painful with rash. P.M. Chills (shaking) temp 99.9.  My normal temp is 67 degrees. March 6: A.M. temp 99.9. Took Tylenol rested all day. Took Tylenol before bed. March 7: A.M. temp 96.5. Feeling better. Still have rash and sore arm.
Shortness of breath, chest pain, numbness, weight loss, white tongue, ringing in ears, nerve pain all over, hair loss.
I left the vaccination center about 12:30 p.m.  All was well until 6 p.m. when I experienced an immediately occurring shortness of breath. accompanied with severe coughing, much phlegm.  I used my regularly prescribed inhaler within 20 minutes and within 30 minutes it calmed down.  Lots of fleeting pains, toes, ankles, elbows, etc.
dizziness; feeling very lethargic; very short of breath; Heart beat is erratic; headaches; chills; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness), LETHARGY (feeling very lethargic), DYSPNOEA (very short of breath), HEART RATE IRREGULAR (Heart beat is erratic) and HEADACHE (headaches) in a 26-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027N21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 05-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 06-Apr-2021, the patient experienced DIZZINESS (dizziness), LETHARGY (feeling very lethargic), DYSPNOEA (very short of breath), HEART RATE IRREGULAR (Heart beat is erratic), HEADACHE (headaches) and CHILLS (chills). At the time of the report, DIZZINESS (dizziness), LETHARGY (feeling very lethargic), DYSPNOEA (very short of breath), HEART RATE IRREGULAR (Heart beat is erratic), HEADACHE (headaches) and CHILLS (chills) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       no concomitant medications reported. no treatment details reported.
Extreme itching and burning Friday evening and night. By Saturday morning, there was a large hive-like rash across my chest. It took Benadryl (2 tablets) and used topical cortisone Saturday and Sunday. By Monday, the rash has gone down and the itching and burning has subsided.
No appetite; Weakness; Congestion; Excruciating sinus headache; Not feeling good; Didn't sleep well; A spontaneous report was received from a consumer concerning a 69-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events not feeling good/ malaise, didn't sleep well/ insomnia, excruciating sinus headache/ sinus headache, no appetite/ decreased appetite, weakness/ asthenia, congestion/ nasal congestion.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 11 Feb 2021, approximately 1 day prior to the onset of the events the patient received their dose of mRNA-1273 (lot/batch: UNKNOWN) via unknown route for prophylaxis of COVID-19 infection.  On 12 Feb 2021, the patient experienced the events not feeling good, didn't sleep well. On 13 Feb 2021, the patient experienced the events excruciating sinus headache. On an unknown date, the patient experienced the events no appetite, weakness, congestion.  Treatment details included Musinex sinus tablets.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events, not feeling good, didn't sleep well, excruciating sinus headache, no appetite, weakness, congestion was not resolved.
As the vaccine was being injected I immediately had a strange taste in my mouth, like 'tin' or like being at the dentist.  4 hours later I drank some coffee and it had no taste.  I quickly learned I could not taste or smell anything.  This went on for 5 days.  Very nauseated and my pain medicine I take was not holding 6 hrs.  My body pain was magnified x10.  I had a hard time staying awake and no appetite.  My Dr. office said they had this reported to them from other patients.  I don't know if I am to get the second vaccine as no one is getting back to me.